Global Cell and Gene Therapy Thawing Equipment Market, By Modality (Benchtop, Portable), Sample (Cell Therapies, Gene Therapies), Type (Manual Thawing System, Automatic Thawing System), Application (Upstream Processing, Downstream Processing), End User (Blood Banks And Transfusion Centers, Hospitals and Diagnostic Laboratories, Research Laboratories And Academic Institutes, Biotechnology and Pharmaceutical Industry, Cord Blood and Stem Cell Banks, Gene Banks, Others), Distribution Channel (Direct Tender, Third Part Distributor, Others) - Industry Trends and Forecast to 2031.
Cell and Gene Therapy Thawing Equipment Market Analysis and Size
Cell and gene therapy thawing equipment has become easy due to the advancement in technology as the number of the key market players are developing and launching new solutions to expand their market. Moreover, the rising healthcare expenditure in developed, as well as developing countries, has fueled the growth of the cell and gene therapy thawing equipment market. The cell and gene therapy thawing equipment market is growing due to the increased incidence of chronic diseases and the rise in technological advancement.
Data Bridge Market Research analyzes that the global cell and gene therapy thawing equipment market, which was USD 823.62 million in 2023, is likely to reach USD 2,382.62 million by 2031 and is expected to undergo a CAGR of 14.20% during the forecast period. The “upstream processing” accounts for the largest market share in the application segment in the cell and gene therapy thawing equipment market due to the greater requirement of thawing before the cells are put up for fermentation. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Modality (Benchtop, Portable), Sample (Cell Therapies, Gene Therapies), Type (Manual Thawing System, Automatic Thawing System), Application (Upstream Processing, Downstream Processing), End User (Blood Banks And Transfusion Centers, Hospitals and Diagnostic Laboratories, Research Laboratories And Academic Institutes, Biotechnology and Pharmaceutical Industry, Cord Blood and Stem Cell Banks, Gene Banks, Others), Distribution Channel (Direct Tender, Third Part Distributor, Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Belgium, Turkey, Ireland, Rest of Europe, China, South Korea, Japan, India, Australia, Singapore, Malaysia, Indonesia, Thailand, Philippines, Rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Egypt, Israel and Rest of Middle East and Africa, Brazil, Argentina, Rest of South America.
|
|
Market Players Covered
|
Pluristem Therapeutics Inc. (U.S.), Genesis BPS (U.S.), Eppendorf AG (Germany), Cytiva (A subsidiary of Danaher Corporation) (U.S.), EDGE Pharma (U.S.), Cook (U.S.), SARSTEDT AG & Co. KG (Germany), Barkey (Germany), Boekel Scientific (U.S.), LABCOLD (U.K.), Sartorius AG (Germany), Helmer Scientific Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Cell and gene therapy thawing instruments are specialized devices designed for the controlled and precise thawing of biological materials used in cell and gene therapies. These instruments play a crucial role in maintaining the viability and functionality of cells or gene-modified materials during the thawing process. They often utilize advanced temperature control systems to prevent thermal stress and ensure uniform thawing. The instruments are equipped with features such as programmable thawing profiles, real-time monitoring, and sterile environments to meet the stringent requirements of cell and gene therapy applications. This technology aids in the safe and efficient thawing of cryopreserved samples, contributing to the overall success of therapeutic interventions in regenerative medicine.
Global Cell and Gene Therapy Thawing Equipment Market Dynamics
Drivers
- Increasing Adoption of Cell and Gene Therapies
The rising prevalence of chronic and genetic diseases has led to a surge in the development and adoption of cell and gene therapies. As these therapies move from experimental stages to commercialization, the demand for reliable thawing instruments grows, driven by the need to efficiently thaw and deliver viable therapeutic materials for patient treatment.
- Rising Investments in Research and Development
The expanding landscape of regenerative medicine prompts significant investments in research and development, with a focus on advancing cell and gene therapies. This increased funding supports the exploration of innovative technologies, including sophisticated thawing instruments, as researchers and companies seek to enhance the overall efficacy and scalability of these ground breaking therapeutic approaches.
Opportunities
- Advanced Instrumentation Development
The evolution of cell and gene therapy thawing instruments presents an opportunity for sophisticated technological advancements. Future developments may focus on creating instruments with enhanced automation, precision, and integration of artificial intelligence for real-time monitoring. This could lead to more user-friendly interfaces and sophisticated temperature control systems, ensuring optimal conditions for thawing and maintaining the integrity of therapeutic materials.
- Integration with Cryopreservation Technologies
Future opportunities lie in the seamless integration of thawing instruments with cryopreservation technologies. This holistic approach can streamline the entire cell and gene therapy workflow, ensuring a standardized and efficient transition from cryopreservation to thawing. Such integration may involve innovative solutions to synchronize temperature control, monitoring, and data management, contributing to a more robust and reliable therapeutic process.
Restraints/Challenges
- High Development Costs
The market faces the challenge of substantial development costs. Research, innovation, and compliance with regulatory standards demand significant financial investments. Manufacturers encounter difficulties in balancing the need for advanced features and compliance with cost-effectiveness, potentially affecting the accessibility of these instruments in the market.
- Cryopreservation Variability
Variability in cryopreservation methods, including differences in freezing rates, cryoprotectant use, and storage conditions, poses a challenge for thawing instrument manufacturers. As thawing effectiveness is closely linked to the quality of cryopreserved materials, addressing the diverse cryopreservation practices across therapies becomes crucial. Standardizing cryopreservation protocols within the industry would enhance the consistency of thawing processes and optimize the performance of thawing instruments.
This cell and gene therapy thawing equipment Market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cell and gene therapy thawing equipment Market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In November 2020, Eppendorg AG had launched the SmartBlock for Cell Thawing in India. The Smart Block Cell Thawing is a foundation for downstream processing. It is easy and convenient for scientists for further use in every cell handling lab
Global Cell and Gene Therapy Thawing Equipment Market Scope
The cell and gene therapy thawing equipment market is segmented on the basis of modality, sample, type, application, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Modality
- Benchtop
- Portable
Sample
- Cell Therapies
- Gene Therapies
Type
- Manual Thawing System
- Automatic Thawing System
Application
- Upstream Processing
- Downstream Processing
End User
- Blood Banks and Transfusion Centers
- Hospitals and Diagnostic Laboratories
- Research Laboratories and Academic Institutes
- Biotechnology and Pharmaceutical Industry
- Cord Blood and Stem Cell Banks
- Gene Banks
- Others
Distribution Channel
- Direct Tender
- Third Party Distributor
- Others
Cell and gene therapy thawing equipment Market Regional Analysis/Insights
The cell and gene therapy thawing equipment market is analyzed and market size insights and trends are provided by modality, sample, type, application, end user and distribution channel as referenced above.
The countries covered in the market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., Israel, Egypt, South Africa, rest of Middle East and Africa, Brazil, Argentina and rest of South America.
The North America is expected to dominate the market and due to higher biologic and biopharmaceuticals production.
The Asia-Pacific is expected to grow with a highest CAGR in the forecast period due to rising research and development activities in cell and gene therapies.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The cell and gene therapy thawing equipment Market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for cell and gene therapy thawing equipment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the cell and gene therapy thawing equipment Market. The data is available for historic period 2010-2020.
Competitive Landscape and Global Cell and Gene Therapy Thawing Equipment Market Share Analysis
The cell and gene therapy thawing equipment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cell and gene therapy thawing equipment market.
Some of the major players operating in the cell and gene therapy thawing equipment market are:
- Pluristem Therapeutics Inc. (U.S.)
- Genesis BPS (U.S.)
- Eppendorf AG (Germany)
- Cytiva (A subsidiary of Danaher Corporation) (U.S.)
- EDGE Pharma (U.S.)
- Cook (U.S.)
- SARSTEDT AG & Co. KG (Germany)
- Barkey (Germany)
- Boekel Scientific (U.S.)
- LABCOLD (U.K.)
- Sartorius AG (Germany)
- Helmer Scientific Inc. (U.S.)
SKU-